Oxafuramine - NLS Pharmaceutics
Alternative Names: NLS-12Latest Information Update: 24 Oct 2023
At a glance
- Originator NLS Pharmaceutics Ltd
- Class Antidementias; Antiparkinsonians
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lewy body disease
Most Recent Events
- 09 Oct 2023 NLS Pharmaceutics files for patent protection under the Patent Cooperation Treaty (PCT) for oxafuramine and its use in preventing and/or treating neurodegenerative diseases
- 09 Oct 2023 Preclinical trials in Lewy body disease in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)